GeekWire

JULY 14, 2020

Adaptive Biotechnologies announced Tuesday that it will sell 8 million shares of its common stock — 6 million of its own, and 2 million from an investor — to help accelerate the company’s work.

Biotechnology 75

Biotechnology Development Microsoft Report 75

GeekWire

JANUARY 13, 2021

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. Sana, which is developing gene and cell therapies that could be used to combat a variety of diseases, previously raised more than $700 million in venture capital. Sana CEO Steve Harr (Sana photo). stake in Sana.

Biotechnology 145

Biotechnology Applications .Net Company 145

GeekWire

OCTOBER 19, 2021

Sana Biotechnology has a new $50 million tool in its toolbox. Beam may also receive additional payments, for instance upon the achievement of development and sales milestones. Sana aims to develop therapeutics for conditions as diverse as cancer, diabetes and cardiovascular disorders. Sana CEO and president Steve Harr.

Biotechnology 135

Biotechnology System Programming Engineering 135

GeekWire

SEPTEMBER 21, 2021

Adaptive co-founders Harlan (left) and Chad Robins on the plaza at the new Adaptive Biotechnology headquarters. After doubling its workforce during the pandemic, Adaptive Biotechnologies finally has room to grow. The company ramped up rapidly as the pandemic accelerated, supporting the development of COVID-19 vaccines.

Biotechnology 98

Biotechnology Real Estate Analysis Research 98

GeekWire

JULY 7, 2021

The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax is also developing shots, geared for older adults, against two viruses that cause pneumonia, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

Development 142

Development Biotechnology Pharmaceuticals .Net 142

GeekWire

DECEMBER 20, 2021

Alexandria Real Equities , a life sciences real estate developer, has bought a 5.2-acre Alexandria bought the property from Bellevue company Pine Forest, which has been planning a large mixed-use development for the site. Alexandria is developing a life sciences hub at Seattle’s almost three-acre Mercer Mega Block.

Real Estate 122

Real Estate Development Biotechnology Journal 122

GeekWire

JUNE 4, 2020

Investors are betting big on the company, which announced a giant $85 million Series B investment round Thursday to help fuel late-stage development of its lead therapeutic candidate called NDX-1017. Depending on the development and approval process, Kawas said the drug could come to market within 2-to-3 years. billion in 2018.

Development 145

Development Biotechnology Research Healthcare 145

GeekWire

MAY 21, 2020

The 4-year-old company is developing cytokines that regulate their own activity in response to biomarkers and metabolic signals, said CEO John Mulligan. Another Seattle biotech company, Nautilus Biotechnology, announced a $76 million funding round Thursday. It is focused initially on immuno-oncology applications.

Development 113

Development Biotechnology Microsoft Applications 113

GeekWire

MAY 27, 2021

New funding: Seattle biotech startup Oisín Biotechnologies has raised a $5 million seed round. It’s currently developing preclinical therapies that target and kill damaged cells that have been biologically turned off or are “senescent” and supposed to die. Oisín Photos). Oisín has raised a total of $9.5

Development 120

Development Biotechnology Travel Study 120

GeekWire

SEPTEMBER 1, 2020

Lumen Bioscience today announced a $16 million Series B round to help support its novel approach to rapid and low-cost drug development. Lumen is led by Finrow, a former senior vice president at Adaptive Biotechnologies, and Chief Science Officer Jim Roberts , the former head of basic sciences at the Fred Hutchinson Cancer Research Institute.

Development 140

Development Biotechnology Travel Programming 140

GeekWire

MARCH 18, 2024

Clockwise, from top left: SEngine Precision CEO Carla Grandori; Joon Care CEO Emily Pesce; FlavorCloud CEO Rathna Sharad; AltPep CEO Valerie Daggett; and Strella Biotechnology CEO Katherine Sizov. The 4-year-old company raised $52.9 million in a Series B round last year. Grandori previously founded Cure First, another Seattle biotech startup.

Company 113

Company Biotechnology Chemicals Survey 113

GeekWire

JULY 2, 2020

OncoSenX is the spinoff of a third company, Seattle-based Oisin Biotechnologies. The researchers said they have selected the two most promising DNA sequences for further testing. Researchers at OncoSenX are using Fusogenix for cancer research on the treatment of solid tumors.

Research 145

Research Pharmaceuticals Biotechnology Development 145

GeekWire

MARCH 8, 2023

(Wexford Science + Technology Image) The University of Washington will move ahead with a building envisioned as a gateway into a reimagined part of its Seattle campus after prevailing in a lawsuit brought by a prominent developer. The UW chose Baltimore-based Wexford Science + Technology to develop the project.

Energy 98

Energy Real Estate Research Development 98

GeekWire

NOVEMBER 9, 2023

Adaptive Biotechnologies CEO Chad Robins speaks at the GeekWire Summit in 2019. He said the businesses are at different stages of maturity, with different capital and development needs. Robins said they’ve been talking for the past 18 months about their two distinct business opportunities.

Biotechnology 107

Biotechnology Real Estate .Net Conference 107

GeekWire

AUGUST 5, 2021

Tadataka Yamada, a pioneer in drug and vaccine development who helped forge numerous biotech companies and spent six years at the Bill and Melinda Gates Foundation as head of global health, died Wednesday morning of natural causes at his home in Seattle. Tadataka “Tachi” Yamada. Twitter Photo via @TachiYamada).

Development 131

Development Pharmaceuticals Biotechnology Industry 131

GeekWire

JANUARY 14, 2022

The Bill & Melinda Gates Foundation has committed $40 million in equity investment and $10 million in grant funding to Vir Biotechnology for the development of therapies against HIV and Malaria, Vir announced Friday. government has been buying to fight Omicron.

Biotechnology 107

Biotechnology Government Research Development 107

GeekWire

APRIL 15, 2021

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. Adaptive Biotechnologies Photo).

Biotechnology 111

Biotechnology Education Web Services Insurance 111

GeekWire

APRIL 12, 2023

Workplace of the Year finalists, clockwise from top left: Adaptive Biotechnologies co-founders Harlan and Chad Robins; the Helion team; Impinj offices in Seattle; Treasury4 team; Blink CEO Karen Clark Cole. This year’s finalists are Adaptive Biotechnologies, Blink, Helion, Impinj and Treasury4. Blink Blink CEO Karen Clark Cole.

Biotechnology 98

Biotechnology Policies Energy Meeting 98

GeekWire

JULY 18, 2023

After announcing in March that it was seeking “strategic alternatives” for its future, Seattle publicly-traded biotechnology company Neoleukin Therapeutics is now planning to merge with New York City-based Neurogene, a gene therapy startup.

Biotechnology 98

Biotechnology Company Development 98

GeekWire

JUNE 23, 2020

Sana Biotechnology today formally announced that it has raised more than $700 million in venture funding — one of the largest venture financing deals in the life sciences industry and one of the biggest rounds on record in Seattle. Steve Harr (Sana Photo). Its executive chairman is Hans Bishop , the former CEO of Juno.

Development 106

Development Company Biotechnology Research 106

GeekWire

AUGUST 23, 2021

Since early July alone, three of those companies went public: drug discovery platform company Absci raised $200 million, vaccine developer Icosavax raised $180 million and nervous system therapeutics company Eliem Therapeutics raised $80 million. It’s an unprecedented trend. billion, according to EndpointsNews.

Biotechnology 130

Biotechnology Company Trends Software 130

GeekWire

JULY 29, 2021

The company, a spin-out from the University of Washington’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax is also developing shots, geared for older adults, against two viruses that cause pneumonia, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

Biotechnology 140

Biotechnology Company Pharmaceuticals Research 140

GeekWire

JUNE 30, 2021

based company developing technologies to accelerate the process of drug discovery, announced today that it plans to go public via an IPO. Absci aims to circumvent current processes for developing protein-based drugs, which often require manufacture in mammalian cells, a cumbersome and difficult method. Absci Photo).

Company 133

Company Biotechnology .Net Programming 133

GeekWire

FEBRUARY 13, 2024

ProfoundBio Photo) ProfoundBio raised $112 million to support development of its pipeline of antibody-drug conjugates (ADCs), agents that recognize a molecular target via an antibody and deliver a toxin or other compound to cells. The company has 95 employees in Suzhou, focused mainly on research and development. billion last year.

Biotechnology 115

Biotechnology Study Development Groups 115

GeekWire

MARCH 8, 2023

(Wexford Science + Technology Image) The University of Washington will move ahead with a building envisioned as a gateway into a reimagined part of its Seattle campus after prevailing in a lawsuit brought by a prominent developer. The UW chose Baltimore-based Wexford Science + Technology to develop the project.

Energy 60

Energy Real Estate Research Development 60

GeekWire

APRIL 18, 2023

The category highlights pioneering health, life science, biotechnology or medical breakthroughs that hold great promise for bettering our lives or improving the healthcare system. Good Therapeutics Graphic) Developing therapeutics that are active only where they are needed in the body has the potential to reduce toxic side effects.

Biotechnology 126

Biotechnology Healthcare Development Software 126

GeekWire

NOVEMBER 19, 2020

Umoja Biopharma raised $53 million to expand development of its CAR T-cell immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. ” Umoja is one of several companies in the Seattle region developing immunotherapy-related technologies. Umoja Biopharma CEO Andy Scharenberg. Umoja Photo).

Biotechnology 145

Biotechnology Research CTO Development 145

GeekWire

MAY 12, 2020

Adaptive Biotechnologies CEO Chad Robins. Adaptive Biotechnologies, which is working with Microsoft and Amgen to fight COVID-19 using its technology for sequencing the human immune system, reported a 65% increase in first quarter revenue , to nearly $21 million. The goal is to develop therapies to treat the virus.

Biotechnology 114

Biotechnology Pharmaceuticals .Net Microsoft 114

GeekWire

DECEMBER 13, 2022

Protheroe previously worked at the UK-based Royal College of Art as director of development and alumni relations. Yang is a biotech vet who worked at Adaptive Biotechnologies, AstraZeneca, and Genentech before joining the Allen Institute, a Seattle-based nonprofit founded almost 20 years ago by Paul Allen, the late Microsoft co-founder.

Nonprofit 120

Nonprofit Biotechnology CTO Engineering 120

GeekWire

APRIL 8, 2024

The five finalists for the Health Innovation of the Year at the GeekWire Awards highlight the multitude of ways that technology is changing healthcare, from treatment in the hospital to the development of new therapeutics. Read more about the finalists and cast your vote below. Read more about the finalists and cast your vote below.

Healthcare 107

Healthcare Biotechnology Research CTO 107

GeekWire

JULY 19, 2021

Eliem has two lead drug candidates in development: ETX-810 for chronic pain conditions and ETX-155 for mood disorders and epilepsy. In June, Seattle-based Nautilus Biotechnology, led by Isilon Systems co-founder Sujal Patel, went public via a SPAC merger. It aims to raise up to $80 million with the IPO.

Biotechnology 114

Biotechnology Pharmaceuticals Groups Development 114

GeekWire

FEBRUARY 17, 2021

Notch Therapeutics is commercializing technologies developed in the labs of Juan-Carlos Zúñiga-Pflücker, left, chair of Notch’s scientific advisory board, and Chief Scientific Officer Peter Zandstra. The biotech company was founded in 2018 and is developing stem cell-derived immunotherapies for cancer. Notch Photo).

Biotechnology 124

Biotechnology Pharmaceuticals Research Development 124

GeekWire

JUNE 17, 2021

Athira Pharma CEO Leen Kawas has been placed on temporary leave until the Seattle area biotechnology company completes a review “stemming from doctoral research Dr. Kawas conducted while at Washington State University.” ” Shares fell sharply in after-hours trading, sinking more than 30%.

Biotechnology 120

Biotechnology Research Journal Study 120

GeekWire

JULY 8, 2021

Absci, which partners with other biopharma companies to identify and develop protein-based drug candidates, has its roots in Portland. Things are different now, said Alexandre, as companies such as Seagen and Adaptive Biotechnologies go public and grow in the region. Bolstering the workforce, increasing regional connections.

Biotechnology 133

Biotechnology Industry Real Estate Company 133

Gizmodo

JANUARY 20, 2022

In the 1990s, that same student might have studied biotechnology, and developed genetic engineering techniques that are solving today’s health crises. In the 1950s, a visionary college student might have pursued a degree in computer science, and helped create our modern digital world. Read more.

Biotechnology 56

Biotechnology Engineering Study Development 56

GeekWire

JANUARY 10, 2022

Adaptive Biotechnologies Photo). Chad Cohen will step down as CFO of Adaptive Biotechnologies on Feb. based Absci deploys AI and other computational methods, as well as laboratory screening techniques, to help drug companies find and develop protein-based drugs. Chad Cohen.

Biotechnology 98

Biotechnology Fractional CTO Real Estate CTO 98

GeekWire

OCTOBER 19, 2021

Sana Biotechnology raised $587 million in its IPO, Absci pulled in $200 million, and vaccine company Icosavax raised more than $180 million. She warns that regional leaders need to focus on talent development at all levels, from K-12 STEM education to research internships, to support regional biotech growth. “I

Biotechnology 130

Biotechnology Real Estate Research Industry 130